Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926389 | 1.00 | ICMT (0.50) | ICMTALDH1A1MAPTRECQLCDC25A | |
| SCHEMBL4926380 | 1.00 | ICMT (0.50) | ICMTALDH1A1MAPTRECQLCDC25A | |
| SCHEMBL4927070 | 0.93 | ICMT (0.57) | ICMTALDH1A1MAPTRECQLCDC25A | |
| SCHEMBL4934348 | 0.93 | ICMT (0.57) | ICMTALDH1A1MAPTRECQLCDC25A | |
| SCHEMBL4927058 | 0.93 | ICMT (0.57) | ICMTALDH1A1MAPTRECQLCDC25A | |
| SCHEMBL4927999 | 0.92 | ICMT (0.62) | ICMTCDC25ACNR2CNR1HDAC3 | |
| SCHEMBL4927994 | 0.92 | ICMT (0.62) | ICMTCDC25ACNR2CNR1HDAC3 | |
| SCHEMBL4930507 | 0.92 | ICMT (0.62) | ICMTCDC25ACNR2CNR1HDAC3 | |
| SCHEMBL4927881 | 0.91 | ICMT (0.64) | ICMTCDC25ACNR2CNR1HDAC3 | |
| SCHEMBL4927887 | 0.91 | ICMT (0.64) | ICMTCDC25ACNR2CNR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | ICMT 4632/4885ALDH1A1 1829/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.